Myelodysplastische Syndrome (MDS)

Schlüsselwörter

myelodysplastische Syndrome - zytogenetische Prognoseevalution - molekulare Marker

Keywords

myelodysplastic syndromes - cytogenetic prognostic evaluation - molecular marker

• Literatur

• 1 Bacher U, Haferlach T, Schnittger S et al. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol 2011; 153: 149-167
• 2 Bejar R, Stevenson K, Abdel-Wahab O et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-2506
• 3 Brunning R, Orazi A, Germing U et al. Myelodysplastic syndromes/neoplasms. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. . Lyon: IARC Press; 2008
• 4 Buesche G, Teoman H, Wilczak W et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 2008; 22: 313-322
• 5 Della Porta MG, Malcovati L, Strupp C et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011; 96: 441-449
• 6 Germing U, Lauseker M, Hildebrandt B et al. Survival, prognostic factors, and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012; in press
• 7 Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088
• 8 Haase D, Germing U, Schanz J et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395
• 9 Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510
• 10 Nachtkamp K, Kündgen A, Strupp C et al. Impact on survival of different treatments for myelodysplastic syndromes (MDS). Leukemia Res 2009; 33: 1024-1028
• 11 Neukirchen J, Schoonen WM, Aul C et al. Incidence and prevalence of patients with myelodysplastic syndromes (MDS) in Duesseldorf 1996-2005. Leuk Res 2011; 35: 1591-1596
• 12 Pellagatti A, Marafioti T, Paterson JC et al. Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. Blood 2010; 115: 2721-2723
• 13 Schanz J, Tüchler H, Sole F et al. A new comprehensive cytogenetic scoring systm for primary myelodysplastic syndromes and oligoblastic AML following MDS derived from an international database merge. J clin Oncol 2011; in press
• 14 Thol F, Friesen I, Damm F et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-2506
• 15 Zipperer E, Pelz D, Nachtkamp K et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009; 94: 729-732